Risk assessment in haematopoietic stem cell transplantation: Conditioning

Best Practice and Research: Clinical Haematology

Volumn 20, Issue 2, 2007, Pages 295-310

  Aschan, Johan ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

busulfan; conditioning; cyclophosphamide; reduced intensity conditioning; total body irradiation

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CARBOPLATIN; CARMUSTINE; CD20 ANTIBODY; CD45 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; IFOSFAMIDE; IODINE 131; LOMUSTINE; MELPHALAN; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RHENIUM 188; THIOTEPA; THYMOCYTE ANTIBODY; YTTRIUM 90;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; APLASTIC ANEMIA; CANCER MORTALITY; CANCER RELAPSE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; EXTERNAL BEAM RADIOTHERAPY; FANCONI ANEMIA; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INDIVIDUALIZATION; MYELOID LEUKEMIA; MYELOMA; MYOCARDITIS; NONHUMAN; PATIENT CARE; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; REDUCED INTENSITY CONDITIONING; REVIEW; RISK ASSESSMENT; STEADY STATE; THALASSEMIA; TREATMENT OUTCOME; WHOLE BODY RADIATION;

BONE MARROW; BUSULFAN; CYCLOPHOSPHAMIDE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; LEUKEMIA, MYELOID; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; TRANSPLANTATION CONDITIONING; WHOLE-BODY IRRADIATION;

EID: 34247238345     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2006.09.004     Document Type: Review

References (79)

1. Jacobson L.O., Marks E.K., Robson M.J., et al. Effect of spleen protection on mortality following x-irradiation. The Journal of Laboratory and Clinical Medicine 34 (1949) 1538-1543
2. Main J.M., and Prehn R.T. Successful skin homografts after the administration of high dosage X radiation and homologous bone marrow. Journal of the National Cancer Institute 15 (1955) 1023-1029
3. Thomas E.D., Lochte Jr. H.L., Cannon J.H., et al. Supralethal whole body irradiation and isologous marrow transplantation in man. The Journal of Clinical Investigation 38 (1959) 1709-1716
4. Thomas E.D., Storb R., Clift R.A., et al. Bone-marrow transplantation. Parts I and II. The New England Journal of Medicine 292 (1975) 832-843 895-902
5. Storb R. Preparative regimens for patients with leukemias and severe aplastic anemia (overview) - biological basis, experimental animal studies and clinical trials at the Fred Hutchinson Cancer Research Center. Bone Marrow Transplantation 14 supplement 4 (1994) S1-S3
6. Brochstein J.A., Kernan N.A., Groshen S., et al. Allogeneic bone marrow transplantation after hyperfractionated total-body irradiation and cyclophosphamide in children with acute leukemia. The New England Journal of Medicine 317 (1987) 1618-1624
7. Deeg H.J., Storb R., Longton G., et al. Single dose or fractionated total body irradiation and autologous marrow transplantation in dogs: effects of exposure rate, fraction size, and fractionation interval on acute and delayed toxicity. International Journal of Radiation Oncology, Biology, Physics 15 (1988) 647-653
8. Thomas E.D., Clift R.A., Hersman J., et al. Marrow transplantation for acute nonlymphoblastic leukemia in first remission using fractionated or single-dose irradiation. International Journal of Radiation Oncology, Biology, Physics 8 (1982) 817-821
9. Deeg H.J., Sullivan K.M., Buckner C.D., et al. Marrow transplantation for acute nonlymphoblastic leukemia in first remission: toxicity and long-term follow-up of patients conditioned with single dose or fractionated total body irradiation. Bone Marrow Transplantation 1 (1986) 151-157
10. Girinsky T., Benhamou E., Bourhis J.H., et al. Prospective randomized comparison of single-dose versus hyperfractionated total-body irradiation in patients with hematologic malignancies. Journal of Clinical Oncology 18 (2000) 981-986
11. Clift R.A., Buckner C.D., Appelbaum F.R., et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: A randomized trial of two irradiation regimens. Blood 76 (1990) 1867-1871
12. Clift R.A., Buckner C.D., Appelbaum F.R., et al. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. Blood 77 (1991) 1660-1665
13. Buckner C.D., Rudolph R., Fefer D., et al. High-dose cyclophosphamide therapy for malignant disease. Toxicity, tumor response, and the effects of stored autologous marrow. Cancer 29 (1972) 357-365
14. Santos G.W., and Owens A.H.J. Allogeneic marrow transplants in cyclophosphamide treated mice. Transplantation Proceedings 1 (1969) 44-46
15. Thomas E.D., Buckner C.D., Storb R., et al. Aplastic anemia treated by marrow transplantation. Lancet 1 (1972) 284-289
16. Storb R., Etzioni R., Anasetti C., et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood 84 (1994) 941-949
17. Fefer A., Einstein A.B., and Thomas E.D. Bone-marrow transplantation for hematologic neoplasia in 16 patients with identical twins. The New England Journal of Medicine 290 (1974) 1389-1393
18. Blume K.G., Forman S.J., O'Donnell M.R., et al. Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies. Blood 69 (1987) 1015-1020
19. Coccia P.F., Strandjord S.E., Warkentin P.I., et al. High-dose cytosine arabinoside and fractionated total-body irradiation: an improved preparative regimen for bone marrow transplantation of children with acute lymphoblastic leukemia in remission. Blood 71 (1988) 888-893
20. Powles R.L., Milliken S., Helenglass G., et al. The use of melphalan in conjunction with total body irradiation as treatment for acute leukaemia. Transplantation Proceedings 21 (1989) 2955-2957
21. Schroeder H., Pinkerton C.R., Powles R.L., et al. High dose melphalan and total body irradiation with autologous marrow rescue in childhood acute lymphoblastic leukaemia after relapse. Bone Marrow Transplantation 7 (1991) 11-15
22. Marks D.I., Forman S.J., Blume K.B., et al. A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission. Biology of Blood and Marrow Transplantation 12 (2006) 438-453
23. Petersen F.B., Buckner C.D., Appelbaum F.R., et al. Etoposide, cyclophosphamide and fractionated total body irradiation as a preparative regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study. Bone Marrow Transplantation 10 (1992) 83-88
24. Spitzer T.R., Peters C., Ortlieb M., et al. Etoposide in combination with cyclophosphamide and total body irradiation or busulfan as conditioning for marrow transplantation in adults and children. International Journal of Radiation Oncology, Biology, Physics 29 (1994) 39-44
25. Petersen F.B., Buckner C.D., Appelbaum F.R., et al. Busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study. Bone Marrow Transplantation 4 (1989) 617-623
26. Riddell S., Appelbaum F.R., Buckner C.D., et al. High-dose cytarabine and total body irradiation with or without cyclophosphamide as a preparative regimen for marrow transplantation for acute leukemia. Journal of Clinical Oncology 6 (1988) 576-582
27. Bender-Gotze C. Late effects of allogeneic bone marrow transplantation in children. Pediatrician 18 (1991) 71-75
28. Socie G., Salooja N., Cohen A., et al. Nonmalignant late effects after allogeneic stem cell transplantation. Blood 101 (2003) 3373-3385
29. Curtis R., Rowlings P., Deeg H., et al. Solid cancers after bone marrow transplantation. The New England Journal of Medicine 336 (1997) 897-904
30. Peters W., Henner W., Grochow L., et al. Clinical and pharmacologic effects of high dose single agent busulfan with autologous bone marrow support in the treatment of solid tumors. Cancer Research 47 (1987) 6402-6406
31. Santos W.G., Tutschka P.J., Brookmeyer R., et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. The New England Journal of Medicine 309 (1983) 1347-1353
32. Tutschka P.J., Copelan E.A., and Klein J.P. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 70 (1987) 1382-1388
33. Blaise D., Maraninchi D., Archimbaud E., et al. Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the Groupe d'Etudes de la Greffe de Moelle Osseuse. Blood 79 (1992) 2578-2582
34. Devergie A., Blaise D., Attal M., et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM). Blood 85 (1995) 2263-2268
35. Clift R.A., Buckner C.D., Thomas E.D., et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 84 (1994) 2036-2043
36. Ringdén O., Ruutu T., Remberger M., et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood 83 (1994) 2723-2730
37. Socie G., Clift R.A., Blaise D., et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood 98 (2001) 3569-3574
38. Ringdén O., Labopin M., Tura S., et al. A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). British Journal of Haematology 93 (1996) 637-645
39. Litzow M.R., Perez W.S., Klein J.P., et al. Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission. British Journal of Haematology 119 (2002) 1115-1124
40. Blume K.G., Kopecky K.J., Henslee-Downey J.P., et al. A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group study. Blood 81 (1993) 2187-2193
41. Bunin N., Aplenc R., Kamani N., et al. Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study. Bone Marrow Transplantation 32 (2003) 543-548
42. Davies S.M., Ramsay N.K., Klein J.P., et al. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. Journal of Clinical Oncology 18 (2000) 340-347
43. Hassan M. The role of busulfan in bone marrow transplantation. Medical oncology (Northwood, London, England) 16 (1999) 166-176
44. Grochow L.B., Jones R.J., Brundrett R.B., et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemotherapy and Pharmacology 25 (1989) 55-61
45. Slattery J.T., Clift R.A., Buckner C.D., et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 89 (1997) 3055-3060
46. Ljungman P., Hassan M., Bekassy A.N., et al. High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients. Bone Marrow Transplantation 20 (1997) 909-913
47. Grochow L.B., Krivit W., Whitley C.B., et al. Busulfan disposition in children. Blood 75 (1990) 1723-1727
48. Schuler U., Schroer S., Kuhnle A., et al. Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted?. Bone Marrow Transplantation 14 (1994) 759-765
49. Andersson B.S., Madden T., Tran H.T., et al. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biology of Blood and Marrow Transplantation 6 (2000) 548-554
50. Hassan Z., Ljungman P., Ringden O., et al. Pharmacokinetics of liposomal busulphan in man. Bone Marrow Transplantation 27 (2001) 479-485
51. Kashyap A., Wingard J., Cagnoni P., et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biology of Blood and Marrow Transplantation 8 (2002) 493-500
52. Kotzerke J., Bunjes D., and Scheinberg D.A. Radioimmunoconjugates in acute leukemia treatment: the future is radiant. Bone Marrow Transplantation 36 (2005) 1021-1026
53. Jurcic J.G., Larson S.M., Sgouros G., et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 100 (2002) 1233-1239
54. Barnes D.W., Corp M.J., Loutit J.F., et al. Treatment of murine leukaemia with X rays and homologous bone marrow; preliminary communication. British Medical Journal (1956) 626-627
55. Weiden P.L., Flournoy N., Thomas E.D., et al. Anti-leukemic effect of graft-versus-host disease in human recipients of allogeneic marrow grafts. The New England Journal of Medicine 300 (1979) 1068-1073
56. Horowitz M.M., Gale R.P., Sondel P.M., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75 (1990) 555-562
57. Kolb H.J., Simoes B., and Schmid C. Cellular immunotherapy after allogeneic stem cell transplantation in hematologic malignancies. Current Opinion in Oncology 16 (2004) 167-173
58. Storb R., Yu C., Wagner J.L., et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 89 (1997) 3048-3054
59. McSweeney P.A., Niederwieser D., Shizuru J.A., et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97 (2001) 3390-3400
60. Sandmaier B.M., and Storb R. Nonmyeloablative therapy and hematopoietic cell transplantation for hematologic disorders. In: Blume K.G., Forman S.J., and Appelbaum F.R. (Eds). Thomas' hematopoietic cell transplantation. 3rd edn. (2004), Blackwell Publishing Ltd, Oxford, UK 1164-1176
61. Sandmaier B.M., Maris M., Maloney D.G., et al. Low-dose total body irradiation (TBI) conditioning for hematopoietic cell transplants (HCT) from HLA-matched related (MRD) and unrelated (URD) donors for patients with hematologic malignancies: a five-year experience (abstract #264). Blood 102 (2003) 78-79
62. Holler E., Kolb H.J., Möller A., et al. Increased serum levels of tumor necrosis factor a precede major complications of bone marrow transplantation. Blood 75 (1990) 1011-1016
63. Kottaridis P.D., Milligan D.W., Chopra R., et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 96 (2000) 2419-2425
64. Baron F., Baker J.E., Storb R., et al. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 104 (2004) 2254-2262
65. Niederwieser D., Gentilini C., Hegenbart U., et al. Allogeneic hematopoietic cell transplantation (HCT) following reduced-intensity conditioning in patients with acute leukemias. Critical Reviews in Oncology/Hematology 56 (2005) 275-281
66. Ho A.Y., Pagliuca A., Kenyon M., et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood 104 (2004) 1616-1623
67. Childs R., Chernoff A., Contentin N., et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. The New England Journal of Medicine 343 (2000) 750-758
68. Barkholt L., Bregni M., Remberger M., et al. Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. Annals of Oncology 17 (2006) 1134-1140
69. Sorror M.L., Maris M.B., Storer B., et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 104 (2004) 961-968
70. Diaconescu R., Flowers C.R., Storer B., et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 104 (2004) 1550-1558
71. Alyea E.P., Kim H.T., Ho V., et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 105 (2005) 1810-1814
72. Petersen F.B., Deeg H.J., Buckner C.D., et al. Marrow transplantation following escalating doses of fractionated total body irradiation and cyclophosphamide-a phase I trial. International Journal of Radiation Oncology, Biology, Physics 23 (1992) 1027-1032
73. Zander A.R., Berger C., Kroger N., et al. High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission. Clinical Cancer Research 3 (1997) 2671-2675
74. Corringham R., Gilmore M., Prentice H.G., et al. High-dose melphalan with autologous bone marrow transplant. Treatment of poor prognosis tumors. Cancer 52 (1983) 1783-1787
75. Schiffman K.S., Bensinger W.I., Appelbaum F.R., et al. Phase II study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease. Bone Marrow Transplantation 17 (1996) 943-950
76. Gaspard M.H., Maraninchi D., Stoppa A.M., et al. Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies. Cancer Chemotherapy and Pharmacology 22 (1988) 256-262
77. Antman K., Ayash L., Elias A., et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. Journal of Clinical Oncology 10 (1992) 102-110
78. Fields K.K., Elfenbein G.J., Perkins J.B., et al. Two novel high-dose treatment regimens for metastatic breast cancer-ifosfamide, carboplatin, plus etoposide and mitoxantrone plus thiotepa: outcomes and toxicities. Seminars in Oncology 20 (1993) 59-66
79. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91 (1998) 756-763